• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童癌症并发发热性中性粒细胞减少症患者降阶梯至门诊口服治疗与住院抗菌治疗的安全性和有效性:一项非劣效性多中心随机临床试验。

Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.

机构信息

Infectious Diseases Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Center of Economics and Social Studies in Health, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

出版信息

Pediatr Blood Cancer. 2020 Jun;67(6):e28251. doi: 10.1002/pbc.28251. Epub 2020 Mar 20.

DOI:10.1002/pbc.28251
PMID:32196898
Abstract

BACKGROUND

It has been suggested that low-risk febrile neutropenia (FN) episodes can be treated in a step-down manner in the outpatient setting. This recommendation has been limited to implementation in middle-income countries due to concerns about infrastructure and lack of trained personnel. We aimed to determine whether early step-down to oral antimicrobial outpatient treatment is not inferior in safety and efficacy to inpatient intravenous treatment in children with low-risk FN.

PROCEDURE

A noninferiority randomized controlled clinical trial was conducted in three hospitals in Mexico City. Low-risk FN was identified in children younger than 18 years. After 48 to 72 hours of intravenous treatment, children were randomly allocated to receive outpatient oral treatment (experimental arm, cefixime) or to continue inpatient treatment (standard of care, cefepime). Daily monitoring was performed until neutropenia resolution. The presence of any unfavorable clinical outcome was the endpoint of interest. We performed a noninferiority test for comparison of proportions.

RESULTS

We identified 1237 FN episodes; 117 cases were randomized: 60 to the outpatient group and 57 for continued inpatient treatment. Of the FN episodes, 100% in the outpatient group and 93% in the inpatient group had a favorable outcome (P < 0.001). The mean duration of antibiotics was 4.1 days (SD 2.5; 95% CI, 3.4-4.8 days) in the outpatient group and 4.4 days (SD 2.5; 95% CI, 3.7-5.0 days) in the inpatient group (P = 0.70).

CONCLUSIONS

In our population, step-down oral outpatient treatment of low-risk FN was as safe and effective as inpatient intravenous treatment. Clinical Trials Identifier: NCT04000711.

摘要

背景

有研究表明,低危发热性中性粒细胞减少症(FN)可在门诊环境中采用降阶梯方式进行治疗。由于对基础设施和缺乏训练有素的人员的担忧,该建议仅限于中低收入国家实施。我们旨在确定在低危 FN 患儿中,早期降阶梯至口服抗菌药物门诊治疗在安全性和疗效方面是否不劣于住院静脉内治疗。

方法

在墨西哥城的 3 家医院进行了一项非劣效性随机对照临床试验。18 岁以下的低危 FN 患儿入选。静脉治疗 48-72 小时后,患儿随机分配接受门诊口服治疗(试验组,头孢克肟)或继续住院治疗(标准治疗,头孢吡肟)。直至中性粒细胞减少症缓解,每日进行监测。关注的终点为任何不良临床结局的发生。我们进行了非劣效性检验,比较比例。

结果

我们共确定了 1237 例 FN 发作;117 例病例被随机分配:60 例进入门诊组,57 例继续住院治疗。门诊组 100%的 FN 发作和住院组 93%的 FN 发作均有良好的结局(P<0.001)。门诊组抗生素的平均使用时间为 4.1 天(SD 2.5;95%CI,3.4-4.8 天),住院组为 4.4 天(SD 2.5;95%CI,3.7-5.0 天)(P=0.70)。

结论

在我们的人群中,低危 FN 的降阶梯口服门诊治疗与住院静脉内治疗同样安全有效。临床试验标识符:NCT04000711。

相似文献

1
Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.儿童癌症并发发热性中性粒细胞减少症患者降阶梯至门诊口服治疗与住院抗菌治疗的安全性和有效性:一项非劣效性多中心随机临床试验。
Pediatr Blood Cancer. 2020 Jun;67(6):e28251. doi: 10.1002/pbc.28251. Epub 2020 Mar 20.
2
Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.门诊与住院 IV 抗生素管理在儿科肿瘤患者低危发热性中性粒细胞减少症中的应用:一项随机试验。
Pediatr Blood Cancer. 2014 Aug;61(8):1427-33. doi: 10.1002/pbc.25012. Epub 2014 Mar 6.
3
First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.儿童癌症中性粒细胞减少症伴低度发热患者首日降阶梯至口服门诊治疗与继续标准治疗的比较:SPOG 2003 FN 多中心研究中的一项随机对照试验。
Pediatr Blood Cancer. 2012 Sep;59(3):423-30. doi: 10.1002/pbc.24076. Epub 2012 Jan 23.
4
Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis.儿童癌症患者发热和中性粒细胞减少症门诊降阶梯管理的经济影响:成本最小化分析。
BMC Health Serv Res. 2024 Aug 24;24(1):981. doi: 10.1186/s12913-024-11442-w.
5
A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patients.一项随机、开放标签、前瞻性对照研究,旨在评估一线经验性静脉注射哌拉西林/他唑巴坦单药治疗与头孢他啶加阿米卡星治疗儿童肿瘤患者发热性中性粒细胞减少症的疗效比较。
Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2733-2737. doi: 10.31557/APJCP.2019.20.9.2733.
6
Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials.癌症和造血干细胞移植受者中性粒细胞减少症患儿经验性发热管理策略:随机试验的系统评价。
J Clin Oncol. 2016 Jun 10;34(17):2054-60. doi: 10.1200/JCO.2015.65.8591. Epub 2016 Mar 28.
7
Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia.低危发热性中性粒细胞减少症儿科患者门诊一级管理的临床路径结果。
Pediatr Blood Cancer. 2019 Jul;66(7):e27679. doi: 10.1002/pbc.27679. Epub 2019 Mar 27.
8
Oral administration of cefixime to lower risk febrile neutropenic children with cancer.
Cancer. 2000 Jun 15;88(12):2848-52. doi: 10.1002/1097-0142(20000615)88:12<2848::aid-cncr27>3.0.co;2-2.
9
Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.口服环丙沙星用于治疗低危发热性中性粒细胞减少症的癌症患儿。
Cancer. 2001 Apr 15;91(8):1563-7. doi: 10.1002/1097-0142(20010415)91:8<1563::aid-cncr1166>3.0.co;2-c.
10
Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial.在有明确病毒呼吸道感染的癌症、发热和中性粒细胞减少症儿童中,不给予抗菌治疗的疗效和安全性:一项随机临床试验。
Clin Microbiol Infect. 2024 Aug;30(8):1029-1034. doi: 10.1016/j.cmi.2024.04.007. Epub 2024 Apr 20.

引用本文的文献

1
Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis.儿童癌症患者发热和中性粒细胞减少症门诊降阶梯管理的经济影响:成本最小化分析。
BMC Health Serv Res. 2024 Aug 24;24(1):981. doi: 10.1186/s12913-024-11442-w.
2
Once-a-Day Ceftriaxone-Amikacin Combination as Empiric Antibiotic Therapy to Enable Outpatient Management of Febrile Neutropenia in Children-16-Year Experience from a Single Institute.每日一次头孢曲松 - 阿米卡星联合用药作为经验性抗生素治疗用于儿童发热性中性粒细胞减少症的门诊管理——来自单一机构的16年经验
South Asian J Cancer. 2022 Sep 2;11(4):370-377. doi: 10.1055/s-0042-1745834. eCollection 2022 Oct.
3
Predictors of Septic Shock or Bacteremia in Children Experiencing Febrile Neutropenia Post-Chemotherapy.
化疗后中性粒细胞减少症发热儿童发生感染性休克或菌血症的预测因素。
J Pediatric Infect Dis Soc. 2022 Dec 5;11(11):498-503. doi: 10.1093/jpids/piac080.
4
Diagnosis and Management of Febrile Neutropenia in Pediatric Oncology Patients-A Systematic Review.儿童肿瘤患者发热性中性粒细胞减少症的诊断与管理——一项系统综述
Diagnostics (Basel). 2022 Jul 25;12(8):1800. doi: 10.3390/diagnostics12081800.